KRAS and colorectal carcinoma: These findings were supported by a study of 37 patients that evaluated the presence of KRAS mutations and p16 hypermethylation in all stages of CRC and found a strong association between detection of ctDNA, and a shorter survival and higher risk of recurrence (92).